I want to thank our two panelists, Dr. Gordon Schutze, the Executive Vice Chair of Pediatrics at Texas Children's Hospital in Houston, and Dr. Sarah Guralnick, Associate Dean for Graduate Medical Education at the University of California--Davis, for joining us today.
Gene Green expresses gratitude to panelists for their participation in the hearing.
Share & report
More from Gene Green
If the administration cares about accountability for 340B, perhaps they should start with implementing the delayed regulatory guidance program.
I appreciate the majority's willingness to hold a hearing on this important issue.
It is imperative that Congress and our federal public health agencies advance policies that will help our fellow Americans struggling with opioid addiction.
Eight years ago, Congress passed the Affordable Care Act to address the HHS Office of Inspector General reports of drug manufacturers overcharging 340B drugs.
Other voices in this conversation
